Iron chelation therapy in MDS: what have we learnt recently?
Patients with myelodysplastic syndromes (MDS) who receive chronic blood transfusions for anaemia are at risk of developing iron overload, which can negatively affect organ function and survival. Evidence suggests that iron chelation therapy can restore iron balance in these patients and may improve their chances of survival. Recently, several guidelines on the management of patients with MDS have been published that address iron overload and the use of iron chelation therapy. While these guidelines differ in some specific details, they generally agree that patients with lower-risk MDS are most likely to develop iron overload and therefore benefit from iron chelation therapy. The oral iron chelator, deferasirox, has been shown to reduce serum ferritin levels and labile plasma iron in patients with MDS, and has an acceptable safety profile. Unlike other iron chelators, deferasirox also appears to inhibit the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) pathway in MDS blast cells, which may lead to additional beneficial effects.
Schmid
Mathias
M
University of Ulm, Ulm, Germany. mathias.schmid@uniklinik-ulm.de
D001565:Benzoates / Q000627:therapeutic use; D015913:Chelation Therapy; D002986:Clinical Trials as Topic; D000077588:Deferasirox; D005293:Ferritins / Q000097:blood; D006801:Humans; D007501:Iron / Q000097:blood; D007502:Iron Chelating Agents / Q000627:therapeutic use*; D019190:Iron Overload / Q000188:drug therapy; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000401:mortality; D014230:Triazoles / Q000627:therapeutic use
D001565:Benzoates; D007502:Iron Chelating Agents; D014230:Triazoles; D005293:Ferritins; D007501:Iron; D000077588:Deferasirox